- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01516333
Replace Glycemic Load and Satiety Study
December 17, 2015 updated by: Frank Greenway, Pennington Biomedical Research Center
Response of Energy Peak Levels After Carbohydrates Are Eaten Glycemic Load and Satiety Study - Phase 1
The study is to examine the effect of four diets differing in glycemic index and amount of carbohydrate on blood sugar and insulin and in hunger, satiety, and vigor.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The extent to which a food raises blood sugar after its consumption is ranked using the Glycemic Index (GI).
Foods with a high GI are those taht cause a large and rapid rise in blood sugar while those with a low GI produce small fluctuations in blood sugar.
It is believed that low GI foods are advantageous for health since the swings in blood sugar and insulin resistant or diabetic.
Interestingly, some studies suggest that low GI food make you less hungry and that this may play an important role in body weight regulation.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Body Mass index between 25-35 kg/m2
- Fasting serum glucose
- Fasting serum glucose < 125 mg/dl
- Free of chronic disease
- Willing to eat only the foods that are provided by the Center during the diet periods
- Willing to abstain from the consumption of alcohol during the diet periods
- Regularly cycling and willing not to become pregnant using birth control (abstinence, barrier methods, partner surgically sterile
- Monophasic birth control (same dose each day)
- Hormone replacement therapy
- Post-menopausal (over 1 year without bleeding)
- Have had partial hysterectomy over the age of 55
- complete hysterectomy at any age
Exclusion Criteria:
- Documented presence of atherosclerotic disease
- Diabetes mellitus
- Renal, hepatic, endocrine, gastrointestinal, hematological or other systemic disease
- Body Mass Index <25 or > 35
- History of drug or alcohol abuse in the last year
- For women, pregnancy, breast feeding or postpartum < 6 months
- History of depression or mental illness requiring treatment or medication within that last 6 months
- Multiple food allergies or significant food preferences or restrictions that would interfere with diet adherence
- Lifestyle or schedule incompatible with the study protocol
- Planned continued use of dietary supplements through the study trial
- Smoking or tobacco use
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Diet 1
High GI; High Carb; High GL
|
Three meals a day
|
|
EXPERIMENTAL: Diet 2
High GI, Low Carb, Med GL
|
Three meals a day
|
|
EXPERIMENTAL: Diet 3
Low GI, High Carb, Med GL
|
Three meals a day
|
|
EXPERIMENTAL: Diet 4
Low GI, Low Carb, Low GL
|
Three meals a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Glucose over time
Time Frame: 1 month
|
Blood glucose demonstrates that diets of different glycemic load result in measurable differences in serum glucose and insulin.
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Analog scores (VAS)
Time Frame: 1 month
|
Hunger, satiety, and vigor will be measured by the visual analog scales.
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: William Cefalu, MD, Pennington Biomedial Research Center
- Principal Investigator: Marlene M Most, PhD, RD, Pennington Biomedical Research Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Primary Completion (ACTUAL)
June 1, 2007
Study Completion (ACTUAL)
June 1, 2007
Study Registration Dates
First Submitted
January 19, 2012
First Submitted That Met QC Criteria
January 19, 2012
First Posted (ESTIMATE)
January 24, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
December 18, 2015
Last Update Submitted That Met QC Criteria
December 17, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PBRC 26026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glycemic Index
-
Rehman Medical Institute - RMINot yet recruitingGlycemic Index and Glycemic LoadPakistan
-
Rehman Medical Institute - RMINot yet recruitingGlycemic Index | Glycemic Load
-
Mondelēz International, Inc.Reading Scientific Services Ltd.Completed
-
Rehman Medical Institute - RMINot yet recruitingGlycemic Index and Glycemic Load
-
Aga Khan UniversityUnknown
-
PepsiCo Global R&DCompletedGlycemic IndexUnited States
-
Danone Asia Pacific Holdings Pte, Ltd.Completed
-
Azienda di Servizi alla Persona di PaviaRecruiting
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCompleted
-
Nutrition Institute, SloveniaValens Int. d.o.o., SlovenijaCompleted
Clinical Trials on High GL 107
-
Dow Pharmaceutical SciencesCompletedAcne VulgarisUnited States, Canada
-
Dow Pharmaceutical SciencesCompletedAcne VulgarisUnited States
-
Memorial Sloan Kettering Cancer CenterGenelux CorporationCompleted
-
Motus GI Medical Technologies LtdCompleted
-
AstraZenecaCompletedPrimary Aldosteronism | HyperaldosteronismUnited States
-
Glac Biotech Co., LtdTerminatedChronic Obstructive Pulmonary Disease | Type 2 DiabetesTaiwan
-
Gliknik Inc.RecruitingImmune ThrombocytopeniaUnited Kingdom
-
Genelux GmbHCompletedA Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal CarcinomatosisPeritoneal CarcinomatosisGermany
-
Genelux GmbHGenelux CorporationCompletedAdvanced Cancers (Solid Tumors)United Kingdom
-
Genelux CorporationNo longer availableAdvanced Stage Cancer (Solid Tumor Disease for 4 Patients) | Acute Myeloid Leukemia (6 Patients)United States